Search results for " Ovary"

showing 10 items of 206 documents

PCOS: metabolic impact and long-term management.

2012

Polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy in women, affecting up to 10% of those in reproductive age. Furthermore, PCOS presents a lifetime risk of type II diabetes, cardiovascular diseases and endometrial cancer. Women with PCOS have increased cardiovascular risk; however, the risk is not the same in all patients and it is necessary to assess an individual risk profile. There is a discrepancy between increased cardiovascular risk at young age and postmenopausal number of cardiovascular events, probablu depending on changes in androgen ovarian function after the forties. However, changes with age of metabolic profile in women with PCOS have not been studied yet an…

AdultSettore MED/09 - Medicina InternaAdolescentComorbiditySettore MED/11 - Malattie Dell'Apparato CardiovascolareMetforminSettore MED/13 - EndocrinologiaDiabetes Mellitus Type 2Cardiovascular DiseasesRisk FactorsObesity AbdominalPCOS Metabolic Syndrome Cardiovascular risk aging insulin resistance hyperandrogenismHypertensionHumansFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceChildAntihypertensive AgentsDyslipidemiasPolycystic Ovary SyndromeMinerva ginecologica
researchProduct

Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.

2013

Background Obesity is known to underlie, at least partially, dyslipidemia in polycystic ovary syndrome (PCOS), but it is unclear whether PCOS status per se increases the risk of alterations of lipoprotein subfractions, which differ in size and atherogenic potential. Our objective was to evaluate whether PCOS influences lipoprotein profile and LDL and HDL subfractions and to study the impact of obesity on these parameters. Materials and methods This was a case–control study conducted in an academic medical centre. The study population consisted of 54 women of fertile age with PCOS and 60 controls adjusted for age and BMI. Biochemical lipid profile and LDL and HDL lipoprotein subfractions (me…

AdultVery low-density lipoproteinmedicine.medical_specialtyendocrine system diseasesClinical BiochemistryBiochemistryBody Mass Indexchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansObesityDyslipidemiasmedicine.diagnostic_testCholesterolbusiness.industryCholesterol HDLCase-control studynutritional and metabolic diseasesCholesterol LDLGeneral MedicineAtherosclerosismedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsEndocrinologychemistryCase-Control StudiesFemalelipids (amino acids peptides and proteins)Lipid profilebusinessBody mass indexDyslipidemiaPolycystic Ovary SyndromeLipoprotein
researchProduct

A 20-year follow-up of young women with polycystic ovary syndrome.

2012

OBJECTIVE: To determine whether hormonal, metabolic, and anthropomorphic parameters change over 20 years in women with polycystic ovary syndrome (PCOS). METHODS: One hundred ninety-three women with PCOS, aged 20–25 years, were diagnosed according to Rotterdam criteria, divided into four phenotypes (A–D), and followed at 5-year intervals for 20 years. Androgens, gonadotropins, insulin, glucose, body mass index, waist circumference, and ovarian volume were measured. RESULTS: At diagnosis, 57% had classic features (phenotype A), 9% had classic features without ovarian findings (phenotype B), 26% had the ovulatory phenotype (C), and 7% were nonhyperandrogenic (D). After 10 years, androgens decr…

Adultendocrine system diseasesPhysiologySettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultInsulin resistanceOvarian functionmedicineHumansInsulinTestosteroneYoung adultInsulin bloodbusiness.industryOvaryFollow up studiesObstetrics and GynecologyDehydroepiandrosteroneOrgan SizeLuteinizing HormoneMiddle Agedmedicine.diseasePolycystic ovaryfemale genital diseases and pregnancy complicationsPolycystic Ovary Syndrome Ovarian function Ovarian aging Androgens Insulin resistance waist circumferencePhenotypeFemaleFollicle Stimulating HormoneInsulin ResistanceWaist CircumferencebusinessBody mass indexHormoneAnovulationFollow-Up StudiesPolycystic Ovary SyndromeObstetrics and gynecology
researchProduct

Increased DHEAs levels in PCO syndrome: evidence for the existence of two subgroups of patients

1986

In 49 patients affected by PCO syndrome the serum levels of dehydroepiandroster-one-sulphate (DHEAs) were determined and correlated with the cfinical presentation and the endocrine pattern. Twenty-three patients (47%) had high DHEAs levels (h-DHEAs patients). They presented a milder clinical presentation (low incidence of amenorrhea) than PCO patients with normal DHEAs levels (n-DHEAs patients). In h-DHEAs patients the finding of a normal DHEAs. response to ACTH and of slightly increased 17OHP serum levels suggested that the elevation of serum DHEAs was not due to an adrenal enzymatic deficiency but to a tonic hyperstimulation of the adrenals. Two subgroups of h-DHEAs patients were identifi…

Adultendocrine systemmedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismDehydroepiandrosteroneEstroneAdrenocorticotropic hormoneBiologychemistry.chemical_compoundEndocrinologyDehydroepiandrosterone sulfateAdrenocorticotropic HormoneInternal medicinepolycyclic compoundsmedicineHumansEndocrine systemskin and connective tissue diseasesAmenorrheaThyrotropin-Releasing HormoneDehydroepiandrosterone SulfateAdrenal glandHyperandrogenismDehydroepiandrosteronemedicine.diseasePolycystic ovaryProlactinmedicine.anatomical_structureEndocrinologychemistryFemalehuman activitieshormones hormone substitutes and hormone antagonistsPolycystic Ovary SyndromeJournal of Endocrinological Investigation
researchProduct

Pituitary-adrenal responses to ovine corticotropin-releasing factor in polycystic ovary syndrome and in other hyperandrogenic patients.

1990

This study was carried out to further characterize the pituitary-adrenal androgen responses of hyperandrogenic patients with 'classic' polycystic ovary syndrome (PCO) and others who were less distinctive and have been called 'PCO-like'. PCO-like patients differed from PCO only in that serum luteinizing hormone (LH) levels were normal and anovulation was not consistent. Ovine corticotropin-releasing factor (CRF) resulted in normal responses of adrenocorticotropic hormone and cortisol in the two groups when compared to controls, while androstenedione (delta 4A) and dehydroepiandrosterone (DHEA) responses were significantly elevated. There were no differences in the responses of PCO and PCO-li…

Adultendocrine systemmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classCorticotropin-Releasing HormoneEndocrinology Diabetes and MetabolismDehydroepiandrosteronePituitary-Adrenal SystemAdrenocorticotropic hormoneAnovulationBasal (phylogenetics)EndocrinologyAdrenocorticotropic HormoneInternal medicinemedicineHumansAndrostenedionebusiness.industryAndrostenedioneObstetrics and GynecologyDehydroepiandrosteroneLuteinizing HormoneAndrogenmedicine.diseasePolycystic ovaryeye diseasesHormonesEndocrinologyOvine corticotropin-releasing factorFemalebusinesshuman activitieshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologyAnovulationPolycystic Ovary SyndromeGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome

1995

Objective To reevaluate the clinical significance of elevations of adrenal androgens in polycystic ovary syndrome (PCOS). Methods Thirty women with PCOS and ten ovulatory controls were evaluated. Serum dehydroepiandrosterone (DHEA) sulfate and 11β-hydroxyandrostenedione were measured before and after 3 and 6 months of GnRH agonist (GnRH-A) therapy. All controls and 15 women with PCOS received intravenous ACTH before and after GnRH-A therapy. Results Twenty-one (70%) of the women with PCOS had elevations of DHEA sulfate, and 16 (53%) had elevations in 11/3-hydroxyandrostenedione. Only two women with PCOS had normal values of both adrenal androgens. After GnRH-A therapy, only 11 subjects (37%…

Adultendocrine systemmedicine.medical_specialtyendocrine system diseasesmedicine.drug_classDehydroepiandrosteroneOvaryPeptide hormonechemistry.chemical_compoundDehydroepiandrosterone sulfateAdrenocorticotropic HormoneInternal medicinepolycyclic compoundsmedicineHumansAndrostenedioneTriptorelin PamoateDehydroepiandrosterone Sulfatebusiness.industryAndrostenedioneObstetrics and GynecologyDehydroepiandrosteroneAndrogenPolycystic ovaryAndrogen secretionmedicine.anatomical_structureEndocrinologychemistryCase-Control StudiesFemaleLeuprolidebusinesshormones hormone substitutes and hormone antagonistsPolycystic Ovary SyndromeObstetrics & Gynecology
researchProduct

Refractory Acne and 21-Hydroxylase Deficiency in a Selected Group of Female Patients.

2009

<i>Background:</i> Excessive androgen production, suspected in women when acne is accompanied by hirsutism and menstrual irregularities, may be due to congenital adrenal hyperplasia. This inherited disorder of cortisol biosynthesis is caused in more than 90–95% of all cases by 21-hydroxylase deficiency (21-OHD). The steroid 21-hydroxylase gene <i>(CYP21)</i> has a high degree of variability. <i>Objective:</i> This study was conducted to evaluate <i>CYP21 </i>gene mutations in a selected group of women with papulopustular and comedonal acne refractory to treatment, irregular menses and hirsutism. <i>Methods:</i> 30 out of 61 women e…

Adultmedicine.medical_specialtyAdolescentDrug ResistancePhysiologyDermatologyAdrenocorticotropic hormoneYoung AdultSettore MED/38 - Pediatria Generale E SpecialisticaPapulopustularInternal medicineAcne VulgarismedicineHumansPoint MutationCongenital adrenal hyperplasiaGenetic TestingRefractory acne Excessive androgen production Non-classical 21-hydroxylase deficiency CYP21 gene mutations.AcnehirsutismAdrenal Hyperplasia Congenitalmedicine.diagnostic_testbiologybusiness.industry17-alpha-HydroxyprogesteroneACTH stimulation test21-Hydroxylasemedicine.diseasePolycystic ovaryEndocrinologybiology.proteinFemaleSteroid 21-HydroxylaseHyperandrogenismbusinessPolycystic Ovary Syndrome
researchProduct

Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndro…

2010

The estradiol-to-testosterone (E2/T) ratio has been investigated in different diseases but few in vivo data are available with regard to its role in women with ovary syndrome (PCOS). The aim of this study was to evaluate the role of the E2/T ratio in the ovulatory function and metabolic pattern in such women.We retrospectively evaluated hyperandrogenemia, clinical hyperandrogenism, ovarian morphology, hypothalamo-hypophyseal axis and metabolic syndrome parameters in a cohort of 202 consecutive women affected by PCOS. An oral glucose tolerance test measured areas under the curve for insulin (AUC(2hIRI)), for glucose (AUC(2hglucose)), and the HOMA-IR and Matsuda index of insulin resistance we…

Adultmedicine.medical_specialtyAdolescentEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectOvarySettore MED/13 - EndocrinologiaCohort StudiesYoung AdultEndocrinologyInsulin resistanceRisk FactorsInternal medicineFollicular phasePCOSmedicineHumansTestosteroneSicilyOvulationProgesteroneMenstrual cycleRetrospective Studiesmedia_commonEstradiolbusiness.industryOvaryHyperandrogenismObstetrics and GynecologyAtherosclerosismedicine.diseasePolycystic ovaryCholesterolEndocrinologymedicine.anatomical_structureFollicular PhaseFemaleMetabolic syndromeHyperandrogenismbusinessAlgorithmsAnovulationPolycystic Ovary SyndromeGynecological Endocrinology
researchProduct

The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabol…

2011

BACKGROUND: Women with polycystic ovary syndrome (PCOS) frequently exhibit central obesity, glucose intolerance, atherogenic dys- lipidemia and hypertension, which are characteristic features of a condition of cardiometabolic risk. Our objective was to investigate the relationship between visceral adiposity index (VAI) and phenotypic characteristics in women with PCOS. METHODS: We conducted a cross-sectional case-control study in our Endocrinology Outpatients Clinic. A total of 220 women with PCOS (Rotterdam definition) and I44 age- and BMI-matched healthy women were studied. We evaluated hyperandrogenemia and clinical hyperandrogenism, ovarian morphology, hypothalamic-hypophyseal axis and …

Adultmedicine.medical_specialtyAdolescentPopulationIntra-Abdominal FatSettore MED/13 - EndocrinologiaInsulin resistanceRisk FactorsInternal medicinemedicinePCOSHumanseducationAdiposityRetrospective StudiesMetabolic Syndromeeducation.field_of_studyGlucose tolerance testmedicine.diagnostic_testbusiness.industryRehabilitationHyperandrogenismCase-control studyObstetrics and GynecologyOdds ratioGlucose Tolerance Testmedicine.diseasePolycystic ovaryOligomenorrheaPhenotypeEndocrinologyReproductive MedicineCardiovascular DiseasesCase-Control StudiesFemaleInsulin ResistanceMetabolic syndromebusinessPolycystic Ovary Syndrome
researchProduct

Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ova…

1995

Objective To determine if the somatostatin analog, octreotide, affects insulin and related peptides and, hence, androgen levels differently between polycystic ovary syndrome (PCOS) patients and controls. Design Prospective controlled trial. Setting Reproductive endocrinology clinic of our medical center. Patients Eleven women with PCOS and six matched ovulatory controls. Interventions Octreotide (100 μg) was administered subcutaneously in the midfollicular phase. Serum was obtained before and at 60, 120, 180, and 240 minutes after octreotide. Main Outcome Measures Fasting insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), T, androstenedion…

Adultmedicine.medical_specialtyAdolescentendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentOctreotideBiologyOctreotideInsulin-like growth factor-binding proteinInternal medicinemedicineHumansInsulinTestosteroneProspective StudiesInsulin-Like Growth Factor ITestosteronePancreatic hormoneInsulinAndrostenedioneObstetrics and GynecologyFastingLuteinizing HormoneAndrogenPolycystic ovaryInsulin-Like Growth Factor Binding ProteinsSomatostatinEndocrinologyReproductive Medicinebiology.proteinFemaleCarrier ProteinsPolycystic Ovary Syndromemedicine.drugFertility and Sterility
researchProduct